Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer by Avery, Steve, Buske, Jamie M., Chen, Doris, Chen, Herman, Chen, Xin, Davidson, Andrew R., Desrosiers, Jean-Nicolas, Dong, Hanqing, Fellah, Noalle, Fernández, David F., Grosso, John, Han, Lu, Hochdorfer, Teri, Johnson, Amber M., Jones, Brian P., Kalinowski, Maciej, Launer-Felty, Katherine D., Lopez, Jorge, Makowski, Teresa, Mastriano, Carolyn, Nguyen, Truong N., Patel, Nitinchandra D., Peng, Zhihui, Potter, Tyler, Pritchard, Robert P., Rane, Anil M., Reeve, Max, Richins, Margaret C., Salazar, Chase A., Salisbury, John J., Simpson, Robert, Tabshey, Liza, Tweed, Erin J., Wahome, Paul G., Walsh-Sayles, Nancy, Willie, Jordan A., Wood, Ethan

Get full text